Conversely, Carfilzomib has emerged as a promising therapeutic agent for alleviating ischemic brain injury by targeting BNIP3L degradation, as suggested in a study by Wu et al. Their findings highlighted the role of proteasomal degradation of BNIP3L and mitophagy dysregulation in cerebral ischemia, shedding light on a novel approach for intervention [189]. Here, BNIP3L is linked to brain ischemia.